A monoclonal antibody, mepolizumab, decreased asthma attacks in Black and Hispanic children and adolescents living in low-income urban neighborhoods. The study identified three networks of genes associated with airway inflammation and asthma attacks that were reduced by the drug.
A Phase 1 clinical trial found a monoclonal antibody to be highly protective against malaria in US adults. L9LS was administered subcutaneously and fully protected 88% of participants from infection.
The National Institutes of Health has updated its Strategic Plan to Cure Hepatitis B, focusing on developing a cure and improving vaccination, screening, and follow-up care strategies. The revised plan aligns with the Department of Health and Human Services' Viral Hepatitis National Strategic Plan.
Scientists used cutting-edge technology to analyze HIV-infected memory CD4+ T cells and found distinct gene expression patterns linked to cell survival and proliferation. These findings suggest that the HIV-infected reservoir may be uniquely susceptible to targeted therapies, offering new hope for cure research.
The Novavax COVID-19 vaccine has been recommended by the CDC for primary series use in US adults ages 18+, following FDA authorization. The vaccine demonstrates 90.4% effectiveness in preventing symptomatic COVID-19 and 100% effectiveness against moderate-to-severe disease. NIH and BARDA supported its development, with NIAID scientists...
A new clinical trial found that COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant, but these antibody levels decrease substantially within 3 months. The immune response to Omicron sub-lineages shows reduced susceptibility to rapidly emerging variants.
The National Institute of Allergy and Infectious Diseases has launched a Phase 1 clinical trial evaluating an mRNA-based vaccine against Nipah virus, which causes severe respiratory and brain swelling. The trial aims to assess the safety, tolerability, and immune response of the investigational vaccine in healthy adults.
A Phase 1 clinical trial of a novel influenza vaccine, BPL-1357, has begun at the National Institutes of Health Clinical Center. The study aims to test the safety and immune response of the vaccine in healthy adult volunteers.
The NIH has launched a clinical trial testing dupilumab, an approved treatment for moderate-to-severe asthma, in children with poorly controlled allergic asthma living in low-income urban neighborhoods. The study aims to define the activity levels of gene networks associated with asthma attacks and improve lung function.
Researchers found that combination broadly neutralizing anti-HIV antibodies (bNAbs) can effectively suppress HIV in individuals without daily antiretroviral therapy (ART), with median duration of time off ART being 39.6 weeks.
A study by NIH found that people with food allergies have a lower risk of becoming infected with SARS-CoV-2. In contrast, obesity and high body mass index (BMI) are associated with increased risk for SARS-CoV-2 infection.
The NIAID has awarded $577 million to establish nine Antiviral Drug Discovery Centers to develop candidate COVID-19 antivirals. The centers will conduct innovative research to identify novel viral targets and develop small molecules and biotherapeutics to block viral targets.
A vaccine candidate for eastern equine encephalitis virus, western equine encephalitis virus, and Venezuelan equine encephalitis virus has been found safe and well-tolerated in a clinical trial. The vaccine induced a neutralizing antibody response against all three viruses.
The NIH has launched a Phase 1 clinical trial to evaluate an investigational preventative vaccine for Epstein-Barr virus (EBV). The study aims to assess the safety and immune response of the EBV gp350-Ferritin nanoparticle vaccine with a saponin-based Matrix-M adjuvant.
The NIH has awarded grants to four institutions to establish Tuberculosis Research Advancement Centers, which will provide focused mentoring, funding support, and training opportunities for new investigators. The centers aim to develop a next-generation of tuberculosis researchers and alleviate the global burden of TB through research.
The COVID-19 Variant Immunologic Landscape (COVAIL) trial aims to understand the immune responses to various additional COVID-19 booster shots and prototype vaccines. The study is being conducted to inform booster shot recommendations and protect against future variants.
Achieving classical herd immunity against SARS-CoV-2 may be unlikely due to virus mutations and asymptomatic transmission. However, widespread use of current public health interventions can control COVID-19 with minimal disruption.
The National Institute of Allergy and Infectious Diseases is conducting a Phase 1 clinical trial evaluating three experimental HIV vaccines based on messenger RNA technology. The study aims to examine the safety and ability of the vaccines to induce an immune response in adults aged 18-55 years.
The NIH is conducting a clinical trial to investigate rare but serious systemic allergic reactions to COVID-19 mRNA vaccines. Participants will receive a second dose of vaccine under controlled conditions to determine safe dosing, while breathing tests and blood draws monitor their response. The study aims to provide insights into mech...
A woman with HIV has achieved 14 months of undetectable HIV levels following a cord blood stem cell transplant to treat acute myeloid leukemia. The study suggests that CCR5Δ32/Δ32 cord stem cell transplantation may be an effective method for achieving HIV remission and cure in individuals requiring such transplants.
The NIH is supporting research on coccidioidomycosis, also known as Valley Fever, with three new awards totaling over $4.5 million. Researchers will focus on developing diagnostics, therapeutics, and vaccines to combat the disease, which affects thousands of people in the US each year.
The NIAID plans to identify prototype pathogens with potential to cause significant human disease, building a framework for rapid research and product development. The institute also focuses on priority pathogens known to cause significant human illness or death.
A new study aims to improve antibody responses in kidney and liver transplant recipients to COVID-19 mRNA vaccine doses, exploring the impact of reduced immunosuppressive medication. The CPAT-ISR trial will enroll up to 400 adults with a history of organ transplants and evaluate the effectiveness of this strategy.
A clinical trial found that combining remdesivir with hyperimmune intravenous immunoglobulin did not improve health status or safety for adults hospitalized with COVID-19. The trial also showed a higher risk of adverse outcomes among patients who generated SARS-CoV-2-neutralizing antibodies before treatment.
A recent study found that adding a booster dose of any COVID-19 vaccine to fully vaccinated adults elicits an immune response and is safe. The trial, sponsored by the NIAID, used 458 adults who received a full regimen of any EUA or approved COVID-19 vaccine.
A clinical trial found that peanut oral immunotherapy desensitized most highly allergic children and induced remission in one-fifth. Younger children and those with lower levels of peanut-specific antibodies were more likely to achieve remission, with 71% of 1-year-olds experiencing remission.
The NIH urges a collaborative effort to characterize coronavirus genetic diversity in multiple species, better understand disease pathogenesis, and develop long-lasting vaccines; permanent immunity remains unknown for COVID-19 vaccines
A novel mRNA-based HIV vaccine has been shown to be safe and elicit desired immune responses in mice and non-human primates. The vaccine prompted a 79% lower per-exposure risk of infection by simian-human immunodeficiency virus compared to unvaccinated animals.
According to a new study funded by NIH, adults with HIV are making progress toward the global target of 95% viral suppression, but children and adolescents are not. The researchers estimated that among adults, 79% were virally suppressed after one year of treatment, while among children and adolescents, only 64% reached this milestone.
A study of 18 COVID-19 patients found that SARS-CoV-2 damages lung tissue by preventing repair and generating healthy tissue, leading to conditions like diffuse alveolar damage. The data may help develop new therapeutics and inform treatment strategies for high-risk patients.
Researchers found that one person relied on high levels of immune cells to control the virus, while another used strong neutralizing antibodies. This study may lead to the development of new treatments to help people with HIV put the virus into remission without taking lifelong medication.
A COVID vaccine booster dose increased levels of neutralizing antibodies against all known SARS-CoV-2 variants of concern. The boost was sustained for at least eight weeks and generated high-level protection against severe disease, suggesting a strong immune memory response and potentially longer lasting immunity.
A clinical trial found that interferon beta-1a plus remdesivir was not superior to remdesivir alone in improving health outcomes for hospitalized adults with COVID-19. Interferon beta-1a was associated with more adverse events and worse outcomes in patients requiring high-flow oxygen.
Researchers identify structure and interaction between HCV E2 protein and CD81 receptor, revealing acidic conditions enhance binding and facilitate cell entry. This discovery provides new leads for developing an HCV vaccine by targeting specific antibodies against the virus.
The NIH study reveals that aerosol exposure directly deposits SARS-CoV-2 deep into the lungs, while fomite exposure leads to initial virus replication in the nose. The findings support public health guidance focused on masking, air filtration, social distancing, and handwashing.
The National Institutes of Health has awarded $53 million in annual funding to 10 research organizations to accelerate HIV cure research. A new grant focuses on HIV cure research in infants and children, while expanding international collaborations and exploring innovative approaches such as CRISPR gene-editing technology.
A new monoclonal antibody called CIS43LS safely prevented malaria for up to nine months in a small clinical trial. The study builds on encouraging early results and will inform additional research to confirm and extend the finding.
The NIH has launched a pilot study to assess the antibody response of kidney transplant recipients to a third dose of an mRNA COVID-19 vaccine. The trial aims to determine if a third dose can overcome the immune suppression caused by lifelong immunosuppressive therapy in this population.
The NIH has renewed grants for seven regional IeDEA centers, awarding $20.8 million in funding to analyze health data from over 2 million people with HIV. The program aims to accelerate progress toward ending the pandemic by addressing local, national, and global questions about illness and death in people with HIV.
A new malaria vaccine has shown unprecedentedly high levels of durable protection in phase 1 trials, potentially reversing the stalled decline of global malaria. The vaccine combines live parasites with antimalarial drugs and has induced sterile hepatic immunity.
A novel adjuvant developed with NIH funding has contributed to the success of COVAXIN, a highly efficacious COVID-19 vaccine. The adjuvant, Alhydroxiquim-II, has been shown to activate key immune receptors and stimulate an effective response against the virus.
Researchers identified an internal communication network in mammals that regulates tissue repair and inflammation. Endogenous retroviruses control this dialogue, affecting the host immune system and antimicrobial defenses.
The NIH's MOMI-VAX study aims to assess antibody responses, transfer of antibodies to infants, and vaccine safety in vaccinated participants and their newborns. The study will enroll up to 750 pregnant individuals and 250 postpartum individuals, followed through the first year after delivery.
The NIH has launched a clinical trial for a novel influenza vaccine that offers long-lasting protection against multiple flu virus strains. The vaccine, known as FluMos-v1, is designed to stimulate antibodies against the HA protein using nanoparticle scaffolds.
A Phase 1/2 clinical trial has begun at the NIH to assess the safety and immunogenicity of different COVID-19 vaccine booster regimens. Participants will receive a single booster dose of the Moderna COVID-19 vaccine, followed by telephone check-ins and in-person follow-up visits for one year.
According to NIH scientists, Salmonella bacteria establish a foothold in the GI tract by hijacking intestinal epithelial cell response, driving colonization and fecal shedding. This process fuels the bacteria's ability to invade neighboring cells and seed the intestine for transmission.
Infants and children with ADA-SCID, a life-threatening inherited immunodeficiency disorder, have regained immune system function after receiving gene therapy. The treatment involves inserting a normal copy of the ADA gene into blood-forming stem cells, offering a one-time procedure with long-term benefits.
A Phase 2b trial will test Dalbavancin for safety and efficacy in treating complicated S. aureus bacteremia in hospitalized adults. The study aims to validate a dalbavancin regimen of one dose a week for two weeks, potentially leading to a shorter and less invasive treatment.
Researchers are enrolling 500 participants, 400 with primary/secondary immune system disorders and 100 without, to study COVID-19 vaccine responses. The study aims to characterize features and adequacy of immune responses and provide valuable information about benefits and potential risks in individuals with immune deficiencies.
The NIH has established a new clinical research network called Childhood Asthma in Urban Settings (CAUSE) to study pediatric asthma in low-income urban settings. The network aims to develop tailored treatment and prevention approaches for children living in these communities.